CN113260373B - 用于诱导神经可塑性的方法和组合物 - Google Patents

用于诱导神经可塑性的方法和组合物 Download PDF

Info

Publication number
CN113260373B
CN113260373B CN201980058427.8A CN201980058427A CN113260373B CN 113260373 B CN113260373 B CN 113260373B CN 201980058427 A CN201980058427 A CN 201980058427A CN 113260373 B CN113260373 B CN 113260373B
Authority
CN
China
Prior art keywords
cells
stroke
amino acid
peptide
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980058427.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113260373A (zh
Inventor
J·西尔弗
Y·罗
F·罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Publication of CN113260373A publication Critical patent/CN113260373A/zh
Application granted granted Critical
Publication of CN113260373B publication Critical patent/CN113260373B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201980058427.8A 2018-09-05 2019-08-29 用于诱导神经可塑性的方法和组合物 Active CN113260373B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862727420P 2018-09-05 2018-09-05
US62/727,420 2018-09-05
PCT/US2019/048698 WO2020051051A1 (en) 2018-09-05 2019-08-29 Methods and compositions for inducing neural plasticity

Publications (2)

Publication Number Publication Date
CN113260373A CN113260373A (zh) 2021-08-13
CN113260373B true CN113260373B (zh) 2025-04-22

Family

ID=69722599

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980058427.8A Active CN113260373B (zh) 2018-09-05 2019-08-29 用于诱导神经可塑性的方法和组合物

Country Status (8)

Country Link
US (2) US12138300B2 (https=)
EP (1) EP3846838A4 (https=)
JP (2) JP7589143B2 (https=)
KR (1) KR102919967B1 (https=)
CN (1) CN113260373B (https=)
AU (1) AU2019334965B2 (https=)
CA (1) CA3111512A1 (https=)
WO (1) WO2020051051A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025092748A1 (zh) * 2023-11-01 2025-05-08 拜西欧斯（北京）生物技术有限公司 多肽衍生物、其药物组合物及其用途
WO2025169981A1 (ja) * 2024-02-07 2025-08-14 第一工業製薬株式会社 脳機能を改善するための環状ペプチド誘導体組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2945108A1 (de) 1979-11-08 1981-05-21 Interatom Internationale Atomreaktorbau Gmbh, 5060 Bergisch Gladbach Faltenbalgkompensator
FR2641360B1 (fr) 1988-12-29 1991-02-22 Commissariat Energie Atomique Compensateur de dilatation monte entre deux tuyauteries
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1995009656A1 (en) 1993-10-01 1995-04-13 New York University Novel receptor-type phosphotyrosine phosphatase-sigma
DE60023920T2 (de) 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphatmimetika und Verfahren zur Behandlung mit Phosphataseinhibitoren HIBITOREN
EP1305333A4 (en) 2000-07-31 2006-04-12 Active Motif PEPTIDE-MEDIATED DELIVERY OF MOLECULES IN CELLS
WO2002083182A2 (en) 2001-04-12 2002-10-24 Mcgill University The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification
US7829087B2 (en) 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
KR100814109B1 (ko) 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
US20090202544A1 (en) 2006-02-02 2009-08-13 The Trustees Of Columbia University In The City Of New York Methods of Treating Diseases by Targeting Silt3
KR100999043B1 (ko) 2007-12-04 2010-12-09 한국생명공학연구원 융합 단백질을 사용하지 않는 인간 단백질 타이로신탈인산화 효소의 활성 도메인 대량 생산 방법
WO2010129681A1 (en) 2009-05-05 2010-11-11 Van Andel Research Institute Methods for treating autophagy-related disorders
WO2010146058A1 (en) 2009-06-15 2010-12-23 Vib Vzw Bace1 inhibitory antibodies
WO2011022462A2 (en) 2009-08-18 2011-02-24 President And Fellows Of Harvard College Neural regeneration
WO2012019086A2 (en) 2010-08-06 2012-02-09 The University Of North Carolina At Chapel Hill Inhibition of lar phosphatase to enhance therapeutic angiogenesis
US9744188B2 (en) 2011-02-18 2017-08-29 President And Fellows Of Harvard College Methods of promoting neuronal outgrowth by gypican 2 that binds to receptor protein tyrosine phosphatase sigma
AU2013235422B2 (en) 2012-03-19 2016-12-15 Buck Institute For Research On Aging APP specific BACE inhibitors (ASBIs) and uses thereof
US9937242B2 (en) 2012-04-09 2018-04-10 Case Western Reserve University Compositions and methods for inhibiting the activity of LAR family phosphatases
US20150084328A1 (en) 2013-09-24 2015-03-26 Witzenmann Gmbh Compensator arrangement

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neural stem cells from protein tyrosine phosphatase sigma knockout mice generate an altered neuronal phenotype in culture;David L Kirkham等;BMC Neuroscience;第第7卷卷;文章号：50 *

Also Published As

Publication number Publication date
EP3846838A4 (en) 2022-06-08
EP3846838A1 (en) 2021-07-14
US12138300B2 (en) 2024-11-12
JP2024113090A (ja) 2024-08-21
KR102919967B1 (ko) 2026-01-30
WO2020051051A1 (en) 2020-03-12
CN113260373A (zh) 2021-08-13
US20250255939A1 (en) 2025-08-14
AU2019334965A1 (en) 2021-03-25
JP7589143B2 (ja) 2024-11-25
AU2019334965B2 (en) 2025-01-23
KR20210054542A (ko) 2021-05-13
CA3111512A1 (en) 2020-03-12
JP2021536461A (ja) 2021-12-27
US20210330757A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
JP7829511B2 (ja) Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法
CN107921085B (zh) 用于治疗衰老相关病症的方法和组合物
US20250255939A1 (en) Methods and compositions for inducing neural plasticity
JP2019501210A (ja) 神経細胞の損失予防及び再生の効能を有するペプチド及びこれを含む組成物
US20170029798A1 (en) Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD)
US20040235732A1 (en) Method for modulating angiogenesis using prokineticin receptor antagonists
ES2407454T3 (es) Métodos de tratamiento de trastornos neuronales utilizando péptidos MNTF y análogos de los mismos
US9073976B2 (en) ND2 peptides and methods of treating neurological disease
US10842852B2 (en) Methods of delivering a polypeptide molecule to Otx2 target cells using an Otx2 targeting peptide
JP5718649B2 (ja) Ｍｎｔｆペプチド組成物およびその使用法
US10160791B2 (en) Protamine in treatment of neuronal injuries
JP5784754B2 (ja) 神経疾患の予防または処置のためのｉｃａｍ−１の使用
US20090291887A1 (en) Proteins of the SDF-1-Family for the Manufacturing of a Medicament
TW202541831A (zh) 治療視神經病變之方法及組合物
Class et al. Patent application title: PROTAMINE IN TREATMENT OF NEURONAL INJURIES
DE10317369A1 (de) proNGF als pharmazeutisch wirksames Mittel zur Behandlung demyelinisierender Erkrankungen

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant